Alpha Tau Completes Enrollment in U.S. Skin Cancer Trial, Moves Closer to FDA Approval

Event summary

  • Alpha Tau Medical has completed enrollment of 88 patients in its ReSTART pivotal trial for recurrent cutaneous squamous cell carcinoma (cSCC).
  • The trial is designed to support a potential FDA pre-market approval (PMA) for Alpha DaRT® in the U.S.
  • Alpha DaRT has received Breakthrough Device Designation from the FDA for this indication.
  • The company has already initiated the PMA modular application process, submitting the first module in January 2026.

The big picture

Alpha Tau's completion of the ReSTART trial enrollment marks a significant step towards bringing Alpha DaRT to market for recurrent cSCC, a condition with rising incidence and limited treatment options. The trial builds on a robust foundation of clinical evidence from multiple countries, positioning Alpha DaRT as a potential breakthrough treatment. The success of this trial could pave the way for Alpha Tau's expansion into other oncology indications, leveraging its innovative alpha-radiation therapy technology.

What we're watching

Regulatory Pathway
The pace at which Alpha Tau can complete and submit the remaining modules of its PMA application will determine the timeline for potential FDA approval.
Clinical Efficacy
The outcomes of the ReSTART trial, particularly the objective response rate and duration of response, will be critical in demonstrating Alpha DaRT's effectiveness.
Market Potential
The ability to secure commercialization agreements and reimbursement coverage for Alpha DaRT in the U.S. will be key to its market success.

Related topics

Biotechnology Oncology